Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>News>This Article

Pfizer, Washington University Announce Collaboration

Published: Thursday, May 20, 2010
Last Updated: Thursday, May 20, 2010
Bookmark and Share
Pfizer will provide Washington University scientists access to research data on a large array of its pharmaceutical candidates for indications discovery.

In a first-of-a-kind collaboration between academia and industry, Pfizer Inc. will give scientists at Washington University School of Medicine in St. Louis unprecedented access to information regarding more than 500 pharmaceuticals and pharmaceutical candidates in a partnership that focuses on discovering new uses for existing compounds.

Under the five-year agreement, Pfizer will provide $22.5 million to Washington University and give its scientists access to research data on a large array of Pfizer pharmaceutical candidates that are currently or were formerly in clinical testing.

Identifying new uses for existing compounds is known as indications discovery. The potential for its success continues to grow, as scientists understand more fully disease mechanisms at the most basic molecular level and the influence of genetic variations on patients’ responses to medications.

“There are two realities in drug discovery,” explains Don Frail, chief scientific officer of Pfizer’s Indications Discovery Unit. “The majority of candidates tested in development do not give the desired result, yet those drugs that do succeed typically have multiple uses. By harnessing the scientific expertise at this leading academic medical center, the collaboration seeks to discover entirely new uses for these compounds in areas of high patient need that might otherwise be left undiscovered.”

The partnership represents a new approach in academia-industry collaborations that has the potential to develop drug compounds more efficiently. By sharing Pfizer’s data on existing compounds, researchers will not have to replicate extensive preclinical studies, thereby shaving years off the time it takes to evaluate new uses for existing drugs.

The agreement builds on the long history of collaboration between the two organizations and brings together scientists from Pfizer and Washington University to jointly propose, design and carry out research on those compounds across a broad range of disease areas in which the University has internationally renowned scientific expertise, such as Alzheimer’s, cancer, diabetes and related metabolic disorders, and asthma and chronic obstructive pulmonary disease.

“We are pleased to see our long-standing relationship with Pfizer evolve into this innovative model of partnership that has the potential to benefit the many patients whose medical needs can’t be met with existing drugs,” says Larry J. Shapiro, MD, executive vice chancellor and dean of Washington University School of Medicine. “We look forward to the many discoveries that will emerge from this collaboration.”

To encourage the exchange of ideas, Pfizer’s Indications Discovery Unit has developed an online portal through which certain Washington University investigators will have unprecedented access to information about Pfizer’s proprietary compounds, including extensive clinical and preclinical data. The compounds have been extensively studied and their mechanisms of action are well-understood. An advisory committee composed of scientists from both Washington University and Pfizer will evaluate proposals for new research that have been co-written by University and Pfizer researchers.

To facilitate the collaboration, Pfizer’s Indications Discovery Unit is moving its laboratories from Chesterfield, Mo., in suburban St. Louis, to the Center of Research Technology and Entrepreneurial Exchange biosciences district (CORTEX), in the heart of St. Louis’ growing biotech corridor, adjacent to Washington University School of Medicine.

The Washington University-Pfizer partnership has its roots in a research agreement the University signed in 1982 with a St. Louis-based predecessor to Pfizer. The new agreement differs from other relationships in which pharmaceutical companies, even in collaborations with academic scientists, have not disclosed propriety information about drug compounds.

“This is a tremendous opportunity for both partners," says Jeffrey Gordon, MD, director of the University's Center for Genome Sciences, who worked closely with Pfizer on the new agreement. “It leverages the complementary strengths and interests of both Washington University and Pfizer. By creating this innovative new framework, academic and pharmaceutical researchers can collaborate in ways that are mutually advantageous for the University, Pfizer and society to meet the needs of patients.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Pfizer to Acquire Hospira for $17B
Companies have into a definitive merger agreement under which Pfizer will acquire Hospira for $90 a share in cash for a total enterprise value of approximately $17 billion.
Thursday, February 05, 2015
Pfizer to Acquire InnoPharma
Under the terms of the agreement, Pfizer will acquire InnoPharma for an upfront cash payment of $225 million, with up to $135 million of contingent milestone payments.
Wednesday, July 16, 2014
Pfizer Confirms Interest in AstraZeneca
Pfizer submitted a preliminary, non-binding indication of interest to the board of directors of AZ in January 2014 regarding a possible merger transaction.
Monday, April 28, 2014
Pfizer Announces Resolutions with DOJ and SEC Related to Certain International Operations
U.S. agencies praise Company’s cooperation and compliance program.
Thursday, August 09, 2012
Pfizer Joins Open-Access Medicinal Chemistry Public-Private Collaboration
Company joins the SGC-led public-private collaboration to generate small molecule inhibitors for proteins involved in epigenetic signalling.
Tuesday, June 15, 2010
Pfizer Receives FDA Approval for Geodon® Capsules for the Adjunctive Maintenance Treatment of Bipolar Disorder in Adults
Data show Geodon used as an adjunct to Lithium or Valproate Is effective in the maintenance treatment of Bipolar I disorder.
Monday, November 23, 2009
Pfizer Announces Partnership with Shanghai Institutes for Biological Sciences for Drug Discovery Activities
Pfizer will provide US$500,000 each year over three years to fund health-related fundamental research projects at SIBS.
Thursday, July 30, 2009
Pfizer Launches Global Regenerative Medicine Research Unit
The new independent research unit will provide new generation of regenerative medicines for major medical needs.
Monday, November 17, 2008
Pfizer Report Demonstrates Value of Conducting Virtual Studies of Drug-Drug Interactions
Scientists have used the Simcyp Simulator to predict the extent of drug-drug interactions for maraviroc, which is used in the treatment of HIV.
Thursday, June 12, 2008
Pfizer and Renovis Extend Research Collaboration to Identify Small Molecule VR1 Antagonists
Pfizer will continue to fund the research and preclinical development efforts at Renovis through June 30, 2008, to advance small molecule VR1 antagonists toward clinical development.
Tuesday, April 10, 2007
Scientific News
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
New Hope for Personalized Treatment of Eczema
Pharmaceutical researchers at Oregon State University have developed a new approach to treat eczema and other inflammatory skin disorders that would use individual tests and advanced science to create personalized treatments based on each person's lipid deficiencies.
Inroads Against Leukaemia
Potential for halting disease in molecule isolated from sea sponges.
Researchers Disguise Drugs As Platelets to Target Cancer
Researchers have for the first time developed a technique that coats anticancer drugs in membranes made from a patient’s own platelets.
HIV Patients Should Be Included in Early Clinical Trials of Anti-TB Drugs
Tuberculosis is the number one cause of death in HIV-infected patients in Africa and a leading cause of death in this population worldwide.
Combination Drug Therapy Shrinks Pancreatic Tumors In Mice
Two drugs that affect the structure and function of DNA have been found to block the growth of pancreatic tumor cells in mice, researchers hope the drugs can soon be tested in humans with the disease.
Seeking A Better Way To Design Drugs
NIH funds research at Worcester Polytechnic Institute to advance a new chemical process for more effective drug development and manufacturing.
Old Drug Performs New Tricks
Cambridge-led research reveals the powers of a "wonder drug" that has lain under the noses of doctors for 50 years.
Diabetes Drugs May Actually Release Sugar Into the Blood
A family of drugs used to treat Type 2 diabetes could promote the release of sugars into the blood - something the drugs are supposed to prevent, Cambridge scientists have claimed.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos